Drugs / MIK665
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04702425 | Jun 2021 → Jul 2024 | acute myeloid leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT03672695 | Nov 2018 → Nov 2022 | acute myeloid leukemia | Servier | Completed | No outcome recorded |
| Phase 1 | NCT02992483 | Jul 2017 → Jun 2019 | diffuse large B-cell lymphoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02979366 | Mar 2017 → May 2020 | acute myeloid leukemia, myelodysplastic syndrome | Servier | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04629443 | Feb 2021 → Aug 2023 | acute myeloid leukemia | Servier | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIK665 | “S 64315 (also referred as MIK665) and azacitidine” NCT04629443 ↗ |
| Known as | S64315 | “S64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion.” NCT03672695 ↗ |
| Action | Inhibit | “a Mcl-1 Inhibitor” NCT02979366 ↗ |
| Route | Intravenous | “via i.v. infusion” NCT02979366 ↗ |
| Target | MCL1 | “MIK665, a Mcl-1 Inhibitor” NCT02992483 ↗ |